PASG - יחס שווי שוק להכנסות החברה Passage Bio Inc.
Passage Bio, Inc. (PASG) relies on AAV vector patents and powerful lobbying under strict FDA oversight. Therapy safety is ensured by cryogenic supply chain logistics. Narrow CNS niches create a defensive moat, despite the binary risks of clinical trials. The current P/S ratio visualizes these fundamentals, while the value determines the metric's magnitude, capturing valuation deviations from the norm.
Passage Bio, Inc. (PASG) - פילוחי מדדים ודוחות פיננסיים
An investment audit of the issuer requires a thorough assessment of market value relative to actual earnings before purchasing assets. This metric is calculated as the ratio of Passage Bio, Inc. (PASG) market capitalization to its total revenue, measuring the premium the market is willing to pay per unit of sales. For this gene therapy developer, this ratio reflects the risks of commercialization delays caused by geopolitical barriers in clinical trials. Analyzing the price-to-sales ratio allows for a balance between expected returns and regulatory threats.
